Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 2/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12430509 | 0.92 | HTR2A (0.46) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL3269917 | 0.88 | CYP2A6 (0.54) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL23188936 | 0.88 | HTR2A (0.53) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL30748374 | 0.88 | CYP2A6 (0.54) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL1800067 | 0.81 | METAP1 (0.52) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL5221227 | 0.81 | HTR2A (0.64) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL30218134 | 0.81 | HTR2A (0.64) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL588130 | 0.80 | CYP2A6 (0.54) | HTR2AHTR2CHTR2BMETAP1PNMT | |
| SCHEMBL6936889 | 0.77 | NPC1 (0.42) | ALDH1A1MEN1KMT2ACYP2A6PARP1 | |
| SCHEMBL6195008 | 0.77 | METAP1 (0.44) | METAP1PNMTALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741693-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | NAGOYA IND SCIENCE RES INST (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) | 2007-09-27 | — | — | US | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1741693-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS | Nagoya Industrial Science Research Institute (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-1070046-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051564-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225528-A1 | Process for Producing Optically Active Alcohol | ADH1C, ADH1A, ADH5 | HTR2A 4038/4885HTR2C 2302/4885HTR2B 2976/4885 |
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | HTR2A 213/4885HTR2C 112/4885HTR2B 332/4885 |
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | HTR2A 677/4885HTR2C 1026/4885HTR2B 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.